Radioimmunoassays Market Is Expected To Reach US$ 564.65 Million By 2033

The global radioimmunoassays market is valued at US$ 420.15 million in 2023 and is predicted to reach US$ 564.65 million by the end of 2033.

By administering a radiolabeled antigen and monitoring the ensuing radioactivity of the antibody component, a radioimmunoassay (RIA) is an in-vitro assay for estimating antibody levels. Solomon Berson and Rosalyn Yalow of the Boranx Veterans Administration Hospital in New York first described the RIA in the 1950s for the measurement of endogenous plasma insulin.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.factmr.com/connectus/sample?flag=S&rep_id=8296?PS

𝐓𝐡𝐞 𝐦𝐞𝐭𝐡𝐨𝐝 𝐜𝐨𝐦𝐛𝐢𝐧𝐞𝐬 𝐭𝐡𝐫𝐞𝐞 𝐟𝐮𝐧𝐝𝐚𝐦𝐞𝐧𝐭𝐚𝐥 𝐢𝐝𝐞𝐚𝐬:

• An immunological response, such as antibody-antigen binding
• Either a competitive binding or displacement response
• Radio emission measurement

𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬 𝐟𝐫𝐨𝐦 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐭𝐮𝐝𝐲

• The global radioimmunoassays market is expected to increase at a CAGR of 3% from 2023 to 2033.
• Germany's market is predicted to expand at a CAGR of 3% during the projected period.
• Sales of reagents & kits are expected to rise at a CAGR of 3.5% during the forecast period.
• Demand for analyzers is predicted to expand at a CAGR of 3% during the next 10 years.

Very small quantities (nanograms, picograms) of substances including antigens, hormones, antibodies, and medicines can be measured or determined using radioimmunoassay. Thus, RIA is employed in narcotics, forensics, and other fields to identify compounds and substances. These are some of the aspects boosting global radioimmunoassays market growth.

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞

Key players in the radioimmunoassays market are making significant efforts to meet the unmet demands of end customers and are placing increasing emphasis on new product development, local supply strategies, mergers and acquisitions, and geographical expansion.

Major companies in the radioimmunoassays market are changing their product pricing trends according to the regional end users' demand. Primarily the focus of market participants is on enhancing the supply chain management system, product standards, safety regulations, and quality control these tactics help them to enhance their market position.

𝐊𝐞𝐲 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐏𝐫𝐨𝐟𝐢𝐥𝐞𝐝

Beckman Coulter, Inc.
Berthold Technologies GmbH & Co. KG
Cisbio Bioassays
DiaSorin SpA
Diasource Immunossays S.A
DRG International, Inc.
Euro Diagnostica AB
IBL International GmbH
Izotop
MilliporeSigma
MP Biomedicals LLC
PerkinElmer, Inc.
Stratec Biomedical AG
Market Developments

Atellica IM SARS-CoV-2 Antigen (CoV2Ag) received an Emergency Use Authorization (EUA) from the US Food and Drug Administration in March 2022.
In January 2020, BioFire Diagnostics, a BioMérieux SA company that specializes in molecular biology, submitted a request to the Food and Drug Administration for approval of their BIOFIRE Blood Culture Identification 2 (BCID2) Panel. In comparison to the first BIOFIRE BCID Panel, the BIOFIRE BCID2 Panel has a larger list of genes associated with antibiotic resistance, significantly more pathogens, and several updated targets.

𝐆𝐞𝐭 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=8296?PS

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐑𝐚𝐝𝐢𝐨𝐢𝐦𝐦𝐮𝐧𝐨𝐚𝐬𝐬𝐚𝐲 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

By Type :

Reagents & Kits
Analyzers
By Application :
Research
Clinical Diagnostics

By End User :

Hospitals
Pharmaceuticals
Clinical Diagnostic Laboratories

By Region :

North America
Latin America
Europe
East Asia
South Asia & Oceania
MEA

𝐌𝐨𝐫𝐞 𝐕𝐚𝐥𝐮𝐚𝐛𝐥𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐨𝐧 𝐎𝐟𝐟𝐞𝐫

Fact.MR, in its new offering, presents an unbiased analysis of the global radioimmunoassays market, presenting historical demand data (2018 to 2022) and forecast statistics for the period of 2023 to 2033.

The study divulges essential insights on the market on the basis of type (reagents & kits, analyzers), application (research, clinical diagnostics), and end user (hospitals, pharmaceuticals, clinical diagnostic laboratories), across five major regions of the world (North America, Europe, Asia Pacific, Latin America, and MEA).

Contact:

Us Sales Office :
11140 Rockville Pike
Suite 400
Rockville, Md 20852
United States
Tel: +1 (628) 251-1583

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com

This release was published on openPR.